Wedbush initiated coverage of Staar Surgical (STAA) with a Neutral rating and $26 price target While the firm believes Staar is a compelling valuation opportunity, trading at significant discounts to both the failed merger consideration and shareholder Broadwood Partners’ publicly stated intrinsic value estimate of $50 per share, Wedbush sees risks related to the company’s China recovery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical Names Interim Co-CEOs Amid Leadership Transition
- Staar Surgical appoints COO Warren Foust, CFO Deborah Andrews as interim co-CEOs
- Seagate upgraded, Tractor Supply downgraded: Wall Street’s top analyst calls
- Staar Surgical appoints new board chair, restructures committees
- Staar Surgical resumed with an Underweight at Morgan Stanley